4D Molecular Therapeutics (FDMT) Cash from Operations (2020 - 2025)
Historic Cash from Operations for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$46.5 million.
- 4D Molecular Therapeutics' Cash from Operations fell 5820.49% to -$46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.5 million, marking a year-over-year decrease of 6185.3%. This contributed to the annual value of -$134.6 million for FY2024, which is 7757.15% down from last year.
- Per 4D Molecular Therapeutics' latest filing, its Cash from Operations stood at -$46.5 million for Q3 2025, which was down 5820.49% from -$43.4 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Cash from Operations ranged from a high of -$1.2 million in Q3 2023 and a low of -$47.8 million during Q1 2025
- Its 5-year average for Cash from Operations is -$26.5 million, with a median of -$23.6 million in 2022.
- Its Cash from Operations has fluctuated over the past 5 years, first surged by 9442.83% in 2023, then plummeted by 240990.61% in 2024.
- 4D Molecular Therapeutics' Cash from Operations (Quarter) stood at -$21.8 million in 2021, then dropped by 1.73% to -$22.2 million in 2022, then fell by 10.97% to -$24.6 million in 2023, then tumbled by 86.06% to -$45.9 million in 2024, then decreased by 1.38% to -$46.5 million in 2025.
- Its Cash from Operations was -$46.5 million in Q3 2025, compared to -$43.4 million in Q2 2025 and -$47.8 million in Q1 2025.